Vaccination and herd immunity: What more do we know?

Current Opinion in Infectious Diseases

Volumn 25, Issue 3, 2012, Pages 243-249

  Rashid, Harunor ^a   Khandaker, Gulam ^a   Booy, Robert ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

basic reproduction number; critical vaccine coverage; herd immunity; herd protection; vaccination

Indexed keywords

CHICKENPOX VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE;

CHICKENPOX; DRUG EFFECT; DRUG EFFICACY; HAEMOPHILUS INFECTION; HERD IMMUNITY; HUMAN; INFECTION PREVENTION; INFLUENZA; MASS IMMUNIZATION; MEASLES; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; REVIEW; ROTAVIRUS INFECTION; VACCINATION;

BACTERIAL VACCINES; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, HERD; VIRAL VACCINES;

EID: 84861045659     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328352f727     Document Type: Review

References (51)

1. May T. Vaccines as community-focused therapy. Expert Rev Vaccines 2003; 2:341-343.
2. Goncalves G. Herd immunity: Recent uses in vaccine assessment. Expert Rev Vaccines 2008; 7:1493-1506.
3. Topley WW, Wilson GS. The spread of bacterial infection. The problem of herd-immunity. J Hyg 1923; 21:243-249.
4. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 1985; 318:323-329.
5. Fine P, Eames K, Heymann DL. 'Herd immunity': A rough guide. Clin Infect Dis 2011; 52:911-916. This review provides a brief overview on theoretical and pragmatic public health perspectives on herd immunity.
6. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-861.
7. Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007; 12:1409-1421.
8. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-743.
9. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-847.
10. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009; 27:1735-1740.
11. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012; 11:11. This review describes the substantial overall benefit of routine Hib immunization on the epidemiology of invasive Hib disease in the United Kingdom, and some variations, perhaps related to variable vaccine effectiveness.
12. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study. BMJ 2004; 329:655-658.
13. Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93:665-669.
14. Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010; 28:4073-4078.
15. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008: CD000422.
16. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2011; 2:e00309-e00310. This review, using data from 10 US states, demonstrates the impact of pneumococcal conjugate vaccination in infants on pneumococcal pneumonia hospitalizations and mortality in all age groups.
17. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet Infect Dis 2011; 11:760-768. An observational study assessing the effect of pneumococcal conjugate vaccination on vaccine type and nonvaccine type disease in England and Wales.
18. Baker JP, Katz SL. Childhood vaccine development: An overview. Pediatr Res 2004; 55:347-356.
19. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2011:CD001478.
20. Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoid: Decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33:1004-1010.
21. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005; 65:1367-1389.
22. Guiso N, Wirsing von Konig CH, Forsyth K, et al. The Global Pertussis Initiative: Report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine 2011; 29:1115-1121. A review of the proceedings of the Round Table Meeting held in Paris, France on 11-12 January 2010 to discuss the epidemiology and detection of pertussis around the globe.
23. Ranganathan S, Tasker R, Booy R, et al. Pertussis is increasing in unimmunized infants: Is a change in policy needed? Arch Dis Child 1999; 80:297-299.
24. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: Pertussis in UK infants. Arch Dis Child 2003; 88:802-806.
25. Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: Meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Hum Vaccin 2011; 7:481-488. This review reports the proceedings of the Fourth GPI Regional Roundtable Meeting held in France in April 2010 on the 'Global Pertussis Initiative' which is an expert forum that aims to raise awareness about pertussis and to recommend effective vaccination strategies for disease control.
26. Millier A, Aballea S, Annemans L, et al. A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoecon Outcomes Res 2012; 12:71-94. This is a review of worldwide economic evaluations of pertussis booster vaccination for adolescents and adults.
27. Leask J, Booy R, McIntyre PB. MMR, Wakefield and The Lancet: What can we learn? Med J Aust 2010; 193:5-7.
28. Centers for Disease Control and Prevention (CDC). Increased transmission and outbreaks of measles: European Region, 2011. Morb Mortal Wkly Rep 2011; 60:1605-1610.
29. Hall R, Jolley D. International measles incidence and immunization coverage. J Infect Dis 2011; 204:S158-S163. In this review, using data from WHO the authors have investigated the decline in measles incidence after immunization with one or two doses of measles-containing vaccine, with or without supplementary immunization activities.
30. van Boven M, Kretzschmar M, Wallinga J, et al. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. J R Soc Interface 2010; 7:1537-1544.
31. Khandaker G, Marshall H, Peadon E, et al. Congenital and neonatal varicella: Impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011; 96:453-456. An analysis using Australian pediatric surveillance data showing reduced incidence of congenital and neonatal varicella in the postvaccination era.
32. Quian J, Ruttimann R, Romero C, et al. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005. Arch Dis Child 2008; 93:845-850.
33. OsterholmMT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44. Here, to assess high-quality evidence about the efficacy and effectiveness of licensed influenza vaccines in the USA, the authors report the findings of a metaanalysis of randomized controlled trials and observational studies that used RT-PCR or viral culture to confirm influenza infections.
34. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: A randomized trial. JAMA 2010; 303:943-950.
35. Glezen WP. Herd protection against influenza. J Clin Virol 2006; 37:237-243.
36. Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010; 202:1626-1633. In this trial involving school children aged 4-11 years, the authors report evidence of herd protection attributed to LAIV for essentially all age groups despite a vaccine mismatch.
37. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly: Systematic review. Vaccine 2010; 29:344-356.
38. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11:482-487. This personal view discusses new methodological developments, such as the use of the cluster-randomized trial, to assess herd protection before the introduction of a vaccine into public health programs.
39. O'Ryan M, Linhares AC. Update on Rotarix: An oral human rotavirus vaccine. Expert Rev Vaccines 2009; 8:1627-1641.
40. Matson DO. The pentavalent rotavirus vaccine, RotaTeq. Semin Pediatr Infect Dis 2006; 17:195-199.
41. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011; 204:980-986. In this study, using nationally representative US data, the authors assessed direct and indirect benefits from rotavirus vaccination among children older than 5 years and adults.
42. Paulke-Korinek M, Kundi M, Rendi-Wagner P, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29:2791-2796. In this study using epidemiological data from a hospital-based surveillance system, the investigators have shown substantial herd effects of rotavirus vaccine in Austria.
43. Anderson EJ. Rotavirus vaccines: Viral shedding and risk of transmission. Lancet Infect Dis 2008; 8:642-649.
44. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26:4978-4983.
45. Andrus JK, de Quadros CA, Castillo Solorzano C, et al. Measles and rubella eradication in the Americas. Vaccine 2011. [Epub ahead of print]
46. Muscat M, Zimmerman L, Bacci S, et al. Toward rubella elimination in Europe: An epidemiological assessment. Vaccine 2012; 30:1999-2007. This is a review on the epidemiology of rubella and congenital rubella syndrome in European countries, 2000-2008. It demonstrates that there is an overall decline in rubella incidence throughout Europe despite the persistence of disease in a few countries.
47. Strebel PM, Gacic-Dobo M, Reef S, Cochi SL. Global use of rubella vaccines, 1980-2009. J Infect Dis 2011; 1:S579-S584.
48. Quinlisk MP. Mumps control today. J Infect Dis 2010; 202:655-656.
49. Dittmann S, Wharton M, Vitek C, et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: Lessons learned. J Infect Dis 2000; 181:S10-S22.
50. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis 2011; 43:683-689. This article provides an up-to-date review on herd immunity of several vaccines. Importantly, it includes discussion on herd immunity of rotavirus and HPV vaccines, not found in other published reviews.
51. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011; 377:2085-2092. In this article, the authors report a significant decrease in the incidence of histopathologically defined high-grade cervical abnormalities in young women in Victoria, Australia after introduction of the HPV vaccination program